Alzheimer’s Imaging Tracer Also Binds Another Protein

Clinicians reading tau-PET scans for dementia may need to consider off-target signal in frontotemporal cases.

Updated on Nov. 5, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a clear glass vial with amber liquid beside a tissue slide on a deep navy field.
Researchers found that flortaucipir, a PET tracer used to detect Alzheimer's tau protein, also binds to TMEM106B, which can distort scans in frontotemporal degeneration. AI Illustration. Upload story photo >

A study of postmortem brain tissue found that flortaucipir, a PET tracer used to detect tau protein in Alzheimer's imaging, also binds to TMEM106B, a lysosomal protein linked to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). The finding suggests some flortaucipir signal in FTLD-TDP may not reflect tau pathology, which matters for how scans are read in people being evaluated for dementia.

Why it matters

Tau-PET scans are widely used to support Alzheimer's diagnosis, so knowing that the tracer can bind to a non-tau protein helps clinicians and researchers interpret results more carefully in frontotemporal conditions. The work points to a possible off-target explanation for some imaging signals rather than a new treatment or screening tool.

This is a postmortem tissue study using fluorescent imaging on samples from 3 cognitively normal controls, 7 Alzheimer's disease cases, and 10 FTLD-TDP cases. Its small sample size means the spatial overlap findings are preliminary and not yet confirmed in larger cohorts.

The players

Flortaucipir

A tau-PET imaging tracer used to detect tau pathology in brain scans for Alzheimer's disease evaluation.

TMEM106B

A lysosomal protein genetically and pathologically linked to frontotemporal lobar degeneration.

The details

Flortaucipir is designed to bind mature, phosphorylated tau, the protein clumps associated with Alzheimer's. In this study, researchers used a fluorescent version of the tracer, called T726, and found that its signal overlapped with TMEM106B, a protein that sits in the cell's lysosomes, the recycling compartments that break down waste. The overlap was strongest in the choroid plexus, the tissue that produces cerebrospinal fluid, and was also seen across hippocampal regions in some FTLD-TDP cases.

Timeline

  1. Study findings were reported in November 2026.

Health Landscape

Tau-PET imaging with flortaucipir has become an important tool for identifying tau pathology in Alzheimer's disease research and clinical evaluation. Findings like this one help define where the tracer's signal is reliable and where it may reflect other biology, which affects how imaging is used across neurodegenerative diseases.

If you or a family member are being evaluated for memory or thinking changes, a tau-PET scan result is one piece of a larger picture that a neurologist will interpret alongside your history and other tests. It is worth asking your doctor how imaging results are weighed in your specific case.

The takeaway

Brain imaging results are most useful when read in context, and this study is a reminder that tracers can bind to more than one target. Ask your clinician how imaging findings are interpreted alongside your symptoms and other evaluations.

Further reading

For broader context on how brain imaging is used in dementia research, see our Alzheimer’s coverage.

Source note: This article includes information reported by Nature.